The Complex Ethics of First in Human Stem Cell Clinical Trials

AJOB Neuroscience

Volumn 3, Issue 2, 2012, Pages 14-16

  Yarborough, Mark ^a   Tempkin, Teresa ^a   Nolta, Jan ^a   Joyce, Nanette ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84860327256     PISSN: 21507740     EISSN: 21507759     Source Type: Journal    
DOI: 10.1080/21507740.2012.675010     Document Type: Article

References (14)

1. Bauer, G., Dao, M. A.Case, S. S. 2008. In vivo biosafety model to assess the risk of adverse events from retroviral and lentiviral vectors. Molecular Therapy, 16: 1308-1315.
2. Caplan, A. I. 2009. Why are MSCs therapeutic? New data: New insight. Journal of Pathology, 217: 318-324.
3. Dey, N. D., Bombard, M. C.Roland, B. P. 2010. Genetically engineered mesenchymal stem cells reduce behavioral deficits in the YAC 128 mouse model of Huntington's disease. Behavioural Brain Research, 214: 193-200.
4. Hess, P. 2012. Intracranial stem cell-based transplantation: Reconsidering the ethics of phase 1 clinical trials in light of irreversible interventions in the brain. AJOB Neuroscience, 3(2): 3-13.
5. Joyce, N., Annett, G., Wirthlin, L., Olson, S., Bauer, G. and Nolta, J. A. 2010. Mesenchymal stem cells for the treatment of neurodegenerative disease. Regenerative Medicine, 5: 933-946.
6. Matthews, D. J., Sugarman, J.Bok, H. 2008. Cell-based interventions for neurologic conditions: Ethical challenges for early human trials. Neurology, 71: 288-293.
7. Meyerrose, T., Olson, S.Pontow, S. 2010. Mesenchymal stem cells for the sustained in vivo delivery of bioactive factors. Advanced Drug Delivery Reviews, 62: 1167-1174.
8. Neuralstem, Inc. 2011. First patient dosed in cervical region in Neuralstem ALS stem cell trial. Press release. Available at: http://investor.neuralstem.com/phoenix.zhtml?c = 203908&p = irol-newsArticle_print&ID = 1633337&highlight = (accessed January 10, 2012)
9. Olson, S. D., Kambal, A.Pollock, K. 2011. Examination of mesenchymal stem cell-mediated RNAi transfer to Huntington's disease affected neuronal cells for reduction of huntingtin. Molecular and Cellular Neurosciences, 49(3): 271-281.
10. Olson, S. D., Pollock, K.Kambal, A. 2012. Genetically engineered mesenchymal stem cells as a proposed therapeutic for Huntington's disease. Molecular Neurobiology, 45(1): 87-98.
11. Sea, K., Gowing, G.Joyce, N. 2011. ALS in California: A report from the First Annual California ALS Research Summit. Neurodegenerative Disease Management, 1: 281-284.
12. Tolar, J., Villeneuve, P. and Keating, A. 2011. Mesenchymal stromal cells for graft-versus-host disease. Human Gene Therapy, 22: 257-262.
13. Yarborough, M. and Sharp, R. R. 2009. Public trust and research a decade later: What have we learned since Jesse Gelsinger's death?. Molecular Genetics and Metabolism, 97(1): 4-5.
14. Zhang, Z. X., Guan, L. X., Zhang, K., Zhang, Q. and Dai, L. J. 2008. A combined procedure to deliver autologous mesenchymal stromal cells to patients with traumatic brain injury. Cytotherapy, 10(2): 134-139.